RSS Feeds
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
- William J. Sandborn, MD;
- Paul Rutgeerts, MD, PhD;
- Robert Enns, MD;
- Stephen B. Hanauer, MD;
- Jean-Frédéric Colombel, MD;
- Remo Panaccione, MD;
- Geert D'Haens, MD;
- Ju Li, PhD;
- Marie R. Rosenfeld, BA;
- Jeffrey D. Kent, MD; and
- Paul F. Pollack, MD
- From the Mayo Clinic, Rochester, Minnesota; Universitaire Ziekenhuizen Leuven and Gasthuisberg, Leuven, Belgium; University of British Columbia, Vancouver, British Columbia, Canada; University of Chicago, Chicago, Illinois; Hôpital Claude Huriez and Centre Hospitalier et Universitaire de Lille, Lille, France; University of Calgary, Calgary, Alberta, Canada; Imelda General Hospital, Bonheiden, Belgium; and Abbott Laboratories, Parsippany, New Jersey, and Abbott Park, Illinois.
-
View larger version:Figure 1. Study flow diagram.*Patients with missing Crohn's Disease Activity Index scores were assumed to have had treatment failure.
-
View larger version:Figure 2. Mean Crohn's Disease Activity Index (CDAI) score at each visit.Remission was defined as a decrease in the CDAI score to <150.
-
View larger version:Figure 3. Summary of subgroup efficacy results.Differences are reported in percentage points, and error bars represent 95% CIs. Interaction P values were 0.88 for concomitant immunosuppressive therapy (azathioprine, 6-mercaptopurine, and methotrexate), 0.01 for concomitant corticosteroid therapy, 0.52 for previous loss of response to infliximab, 0.28 for previous intolerance of infliximab, 0.17 for previous loss of response to and intolerance of infliximab, 0.36 for presence of antibodies to infliximab at screening, and 0.67 for C-reactive protein (CRP) concentration ≥10 mg/L at week 0. *Missing data for 1 patient in the placebo group. †Missing data for 7 patients in the placebo group and 6 patients in the adalimumab group.
Related Clinical Content
